<DOC>
	<DOCNO>NCT00754117</DOCNO>
	<brief_summary>Newly diagnose DLCL patient baselne FDG-PET part initial staging ( PET-1 ) . Patients undergo 2 cycle chemotherapy R/CHOP . 14 21 day follow cycle 2 R/CHOP , patient undergo repeat FDG-PET scan ( PET-2 ) . They complete therapy plan . Following completion therapy , standard response assessment perform , include CT scan chest , abdomen pelvis FDG-PET scan ( PET-3 ) .</brief_summary>
	<brief_title>Early Response Assessment Diffuse Large B-Cell Lymphoma ( DLCL ) Patients 18-fluoro-2-deoxyglycose Positron Emission Tomography ( FDG-PET )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<criteria>Patients must histologically cytologically confirm diagnosis CD20+ diffuse large B cell lymphoma ( LBCL ) stage , include subtypes mediastinal large B cell , centroblastic , immunoblastic , T cell rich B cell anaplastic B cell lymphoma Patients must receive prior antilymphoma therapy . Age &gt; 18 year . Patients must treatment plan include R/CHOP R/CHOP follow radiotherapy . Ability understand willingness sign write informed consent document . Patients know HIV infection . Patients , opinion treat oncologist , unable undergo R/CHOP chemotherapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>diffuse large b cell lymphoma</keyword>
	<keyword>newly diagnose</keyword>
</DOC>